These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19412494)

  • 1. Atomoxetine: a novel treatment for child and adult ADHD.
    Ledbetter M
    Neuropsychiatr Dis Treat; 2006 Dec; 2(4):455-66. PubMed ID: 19412494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
    Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.
    Christman AK; Fermo JD; Markowitz JS
    Pharmacotherapy; 2004 Aug; 24(8):1020-36. PubMed ID: 15338851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Harrington MJ; Burke WJ
    Expert Opin Pharmacother; 2003 Jul; 4(7):1165-74. PubMed ID: 12831341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
    Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
    Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system.
    Kasi PM; Mounzer R; Gleeson GH
    Case Rep Med; 2011; 2011():952584. PubMed ID: 21765848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the pharmacokinetics of extended release viloxazine in the treatment of children with attention-deficit/hyperactivity disorder.
    Childress A; Burton S
    Expert Opin Drug Metab Toxicol; 2022 Jun; 18(6):357-366. PubMed ID: 35848085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
    Corman SL; Fedutes BA; Culley CM
    Am J Health Syst Pharm; 2004 Nov; 61(22):2391-9. PubMed ID: 15581262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
    Simpson D; Plosker GL
    Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effectiveness of atomoxetine in children, adolescents, and adults with ADHD. A systematic overview].
    Sevecke K; Battel S; Dittmann RW; Lehmkuhl G; Döpfner M
    Nervenarzt; 2006 Mar; 77(3):294, 297-300, 302-4 passim. PubMed ID: 16133434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
    Simpson D; Plosker GL
    CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
    Spencer T; Heiligenstein JH; Biederman J; Faries DE; Kratochvil CJ; Conners CK; Potter WZ
    J Clin Psychiatry; 2002 Dec; 63(12):1140-7. PubMed ID: 12523874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
    Walker DJ; Mason O; Clemow DB; Day KA
    Postgrad Med; 2015; 127(7):686-701. PubMed ID: 26343377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
    Wernicke JF; Kratochvil CJ
    J Clin Psychiatry; 2002; 63 Suppl 12():50-5. PubMed ID: 12562062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities.
    Clemow DB; Bushe C; Mancini M; Ossipov MH; Upadhyaya H
    Neuropsychiatr Dis Treat; 2017; 13():357-371. PubMed ID: 28223809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
    Gaillez C; Sorbara F; Perrin E
    Encephale; 2007 Sep; 33(4 Pt 1):621-8. PubMed ID: 18033153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased prefrontal hemodynamic change after atomoxetine administration in pediatric attention-deficit/hyperactivity disorder as measured by near-infrared spectroscopy.
    Ota T; Iida J; Nakanishi Y; Sawada S; Matsuura H; Yamamuro K; Ueda S; Uratani M; Kishimoto N; Negoro H; Kishimoto T
    Psychiatry Clin Neurosci; 2015 Mar; 69(3):161-70. PubMed ID: 25359429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine.
    Simpson D; Perry CM
    Paediatr Drugs; 2003; 5(6):407-15; discussion 416-7. PubMed ID: 12765489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine treatment of attention-deficit/hyperactivity disorder.
    Eiland LS; Guest AL
    Ann Pharmacother; 2004 Jan; 38(1):86-90. PubMed ID: 14742801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.